Leerink Partners analyst Marc Goodman has maintained their bullish stance on JAZZ stock, giving a Buy rating yesterday.
Marc Goodman has given his Buy rating due to a combination of factors that reflect positively on Jazz Pharmaceuticals’ future performance. The company’s recent quarterly results met expectations, with earnings per share (EPS) surpassing projections due to a strategic reduction in research and development expenses. This shift in spending priorities has restored investor confidence, particularly after previous concerns about increased R&D costs impacting EPS.
Additionally, the anticipation of positive data from the Zani gastric study and the favorable settlement regarding the loss of exclusivity (LOE) for Epidiolex have bolstered investor sentiment. The extension of the LOE timeline into the late 2030s has alleviated significant investor concerns, contributing to a recent uptick in the stock’s value. These factors, combined with the company’s solid financial guidance for 2025, underpin Goodman’s optimistic outlook and Buy rating for Jazz Pharmaceuticals.
In another report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $176.00 price target.
JAZZ’s price has also changed moderately for the past six months – from $114.290 to $144.170, which is a 26.14% increase.